In Section C, participants will obtain ABBV-744 and oral navitoclax. In Segment D, contributors will obtain ABBV-744 and ruxolitinib. Individuals will obtain treatment until condition progression or perhaps the individuals are not able to tolerate the study drugs. Ubiquitin-connected proteins that regulate The soundness of essential super enhancer-mediated proteins have https://robertc332pbl5.dekaronwiki.com/user